Clinical Trial: The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07788573) titled 'The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment' on Aug. 19.

Brief Summary: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting M...